BR112015022218A2 - composições e sua utilização para tratar complicações da hemorragia subaracnóidea aneurismática - Google Patents

composições e sua utilização para tratar complicações da hemorragia subaracnóidea aneurismática

Info

Publication number
BR112015022218A2
BR112015022218A2 BR112015022218A BR112015022218A BR112015022218A2 BR 112015022218 A2 BR112015022218 A2 BR 112015022218A2 BR 112015022218 A BR112015022218 A BR 112015022218A BR 112015022218 A BR112015022218 A BR 112015022218A BR 112015022218 A2 BR112015022218 A2 BR 112015022218A2
Authority
BR
Brazil
Prior art keywords
brain injury
interruption
compositions
abstract
subarachnoid hemorrhage
Prior art date
Application number
BR112015022218A
Other languages
English (en)
Portuguese (pt)
Inventor
Loch Macdonald R
Original Assignee
Edge Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edge Therapeutics Inc filed Critical Edge Therapeutics Inc
Publication of BR112015022218A2 publication Critical patent/BR112015022218A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015022218A 2013-03-11 2014-03-11 composições e sua utilização para tratar complicações da hemorragia subaracnóidea aneurismática BR112015022218A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/793,767 US10092524B2 (en) 2008-06-11 2013-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
PCT/US2014/023748 WO2014164904A1 (en) 2013-03-11 2014-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage

Publications (1)

Publication Number Publication Date
BR112015022218A2 true BR112015022218A2 (pt) 2017-07-18

Family

ID=49157870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022218A BR112015022218A2 (pt) 2013-03-11 2014-03-11 composições e sua utilização para tratar complicações da hemorragia subaracnóidea aneurismática

Country Status (14)

Country Link
US (2) US10092524B2 (enExample)
EP (1) EP2968166A4 (enExample)
JP (1) JP2016512527A (enExample)
KR (1) KR101902319B1 (enExample)
CN (1) CN105324108A (enExample)
AU (1) AU2014248877A1 (enExample)
BR (1) BR112015022218A2 (enExample)
CA (1) CA2905327A1 (enExample)
GB (1) GB2528801A (enExample)
HK (1) HK1216002A1 (enExample)
NZ (1) NZ629730A (enExample)
RU (1) RU2015143206A (enExample)
SG (1) SG11201507398XA (enExample)
WO (1) WO2014164904A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
CA2986692A1 (en) * 2015-05-29 2016-12-08 Edge Therapeutics, Inc. Compositions and methods for reducing visual loss
WO2017176914A1 (en) * 2016-04-07 2017-10-12 Edge Therapeutics, Inc. Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneurysmal subarachnoid hemorrhage
CN108403629B (zh) * 2018-04-26 2019-11-05 徐州医科大学 一种尼莫地平口服长效悬浮液及其制备方法
WO2020227558A2 (en) * 2019-05-07 2020-11-12 Yale University Maximizing distribution and minimizing washout of injectates in bone and method for enhanced aspirate extraction
WO2020235947A1 (ko) * 2019-05-22 2020-11-26 경북대학교 산학협력단 Cacb1 유래 펩타이드, Cacb1 유래 펩타이드의 변이체 및 이의 용도
WO2021168351A1 (en) * 2020-02-20 2021-08-26 Postsurgical Therapeutics, Inc. Brain drug delivery system and method
WO2021262725A1 (en) * 2020-06-22 2021-12-30 Curelator, Inc. Systems and methods for segmentation of a user population based on time-based variations in biomarker levels
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
JP2024508888A (ja) * 2021-03-03 2024-02-28 クランメド リミテッド 一時的塞栓剤としてのアルギネートベースの粒子
WO2025151741A1 (en) * 2024-01-10 2025-07-17 Brown David Donaldson Methods of treating migraine headache or tension headache with hyaluronic acid

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
ATE133087T1 (de) 1989-05-04 1996-02-15 Southern Res Inst Einkapselungsverfahren
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
EP0740791A4 (en) 1994-01-05 2000-04-05 Arqule Inc SYSTEMATIC MODULAR PRODUCTION OF AMINIMID AND OXAZOLONE-BASED MOLECULES WITH SELECTED PROPERTIES
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
AT404429B (de) 1995-06-09 1998-11-25 Immuno Ag Anti-plasma-antikörper-präparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
WO1998027963A2 (en) 1996-12-20 1998-07-02 Alza Corporation Gel composition and methods
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
WO1999018949A1 (en) 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
JP2000070366A (ja) 1998-09-02 2000-03-07 Arute:Kk 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法
US20050214227A1 (en) * 1999-03-08 2005-09-29 Powderject Research Limited Microparticle formulations for sustained-release of bioactive compounds
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
CA2396016A1 (en) 1999-12-29 2001-07-05 Andy Bernhardt System for reconstituting pastes and methods of using same
EP1250166B1 (en) 2000-01-25 2010-03-17 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002003406A (ja) 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
AU2002335658A1 (en) 2001-08-31 2003-03-18 Neuron Therapeutics, Inc. Treatment of neurologic hemorrhage
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
EP1459727B1 (en) 2001-11-22 2010-06-09 Japan Science and Technology Agency Nonhuman model animal unresponsive to immunopotentiating synthetic compound
JP2005524657A (ja) 2002-02-27 2005-08-18 ファーメイン， エルティーディー． 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
TW200307011A (en) 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
CN1671400A (zh) 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
DK1553927T3 (da) 2002-09-11 2011-01-31 Elan Pharma Int Ltd Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
JP4092994B2 (ja) 2002-09-13 2008-05-28 ニプロ株式会社 プレフィルドシリンジキット
WO2004047768A2 (en) 2002-11-26 2004-06-10 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
JP2007515392A (ja) 2003-04-10 2007-06-14 ピーアール ファーマシューティカルズ，インコーポレイテッド エマルジョンベースの微粒子の製造のための方法
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CA2533592C (en) 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
WO2005042048A2 (en) 2003-10-22 2005-05-12 Encelle, Inc. Bioactive hydrogel compositions for regenerating connective tissue
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006084005A2 (en) 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
EP1893230A2 (en) 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
JP2009501188A (ja) 2005-07-15 2009-01-15 ノボ ノルディスク ヘルス ケア アーゲー 抗血小板療法で治療される患者における脳内出血（ＩＣＨ）後の出血増大及び／又は浮腫形成を予防又は軽減するための第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
GB0515492D0 (en) 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
WO2007047406A2 (en) 2005-10-14 2007-04-26 Transform Pharmaceuticals, Inc. Liquid pharmaceutical compositions of nimodipine
JP2009516751A (ja) 2005-11-21 2009-04-23 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ 神経保護のための小分子化合物を使用する方法
EP2108041A1 (en) 2007-01-18 2009-10-14 Reckitt Benckiser N.V. Dosage element and a method of manufacturing a dosage element
WO2008134541A2 (en) 2007-04-25 2008-11-06 Musculoskeletal Transplant Foundation Reinforced biological mesh for surgical reinforcement
US9005183B2 (en) 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
KR101554250B1 (ko) 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US20120164226A1 (en) 2007-06-11 2012-06-28 Leuthner Brian A Compositions and Methods for Improving Prognosis of a Human with Subarachnoid Hemorrhage
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
CN102131496B (zh) 2008-08-22 2013-10-23 雷克特本克斯尔保健(英国)有限公司 组合物的改进或与组合物有关的改进
EP2331082B1 (en) 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
EP2334288B1 (en) 2008-09-18 2021-05-19 Evonik Corporation Microencapsulation process with solvent and salt
US20100216948A1 (en) 2009-01-23 2010-08-26 Tipton Arthur J Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
WO2010085609A2 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US20100291027A1 (en) 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
US20110033463A1 (en) 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
WO2011087689A2 (en) 2009-12-22 2011-07-21 Surmodics Pharmaceuticals,Inc. Emulsion-based process for preparing microparticles and workhead assembly for use with same
GB2490084A (en) 2010-02-22 2012-10-17 Edge Therapeutics Inc Methods and compositions to treat hemorrhagic conditions of the brain
US9504643B2 (en) 2010-03-29 2016-11-29 Evonik Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof

Also Published As

Publication number Publication date
NZ629730A (en) 2017-03-31
KR101902319B1 (ko) 2018-09-28
JP2016512527A (ja) 2016-04-28
RU2015143206A (ru) 2017-04-18
US20160324796A1 (en) 2016-11-10
GB201516997D0 (en) 2015-11-11
AU2014248877A1 (en) 2015-10-01
EP2968166A1 (en) 2016-01-20
SG11201507398XA (en) 2015-10-29
EP2968166A4 (en) 2016-10-05
US20130243864A1 (en) 2013-09-19
KR20150136084A (ko) 2015-12-04
GB2528801A (en) 2016-02-03
AU2014248877A8 (en) 2015-10-29
HK1216002A1 (zh) 2016-10-07
CN105324108A (zh) 2016-02-10
US10092524B2 (en) 2018-10-09
WO2014164904A1 (en) 2014-10-09
CA2905327A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
BR112015022218A2 (pt) composições e sua utilização para tratar complicações da hemorragia subaracnóidea aneurismática
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
CO6551721A2 (es) Moduladores de cinasa novedosos
MX2022010225A (es) Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
BR112015027790A2 (pt) Placa de osteossíntese e segmento para uma placa de osteossíntese
EP3313875A4 (en) Methods and compositions for treatment of symptoms associated with intracranial hemorrhage
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112016010454A2 (pt) métodos para tratar uma taupatia
BR112018004620A2 (pt) moduladores da expressão de kras
BR112016013485A2 (pt) Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s)
CR20170219A (es) Inhibidores del bromodominio
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
MX386085B (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa
GB201317446D0 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
BR112016024186A2 (pt) caixa de coluna vertebral
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
BR112013022234A2 (pt) emulsão de dodecafluorpentano como uma terapia de acidente vascular cerebral e isquemia
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
BR112014027965A2 (pt) composições de polimorfos, métodos de produção, e usos das mesmas
BR112015024625A2 (pt) composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento
BR112017005200A2 (pt) composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo.
CL2015003264A1 (es) Composición antirregurgitación que mantiene la motilidad intestinal
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 07/01/2020.